Study Title: Epigallocatechin gallate enhances sympathetic heart rate variability and decreases blood pressure in obese subjects: a randomized control trial
Summary
This study investigated the effects of epigallocatechin gallate (EGCG) on blood pressure (BP) and the autonomic nervous system in obese subjects. The results showed that after 8 weeks of EGCG treatment, systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean arterial pressure (MAP) significantly decreased, while the low-frequency (LF) to high-frequency power (HF) ratio (LF/HF ratio) significantly increased. These changes indicated a shift toward sympathetic dominance, either directly or indirectly after BP lowering.
Correlations and Conclusions
The study found positive correlations between SBP and obesity parameters, leptin, insulin, and insulin resistance, as well as a negative correlation with insulin sensitivity. DBP was positively correlated with age and HF in normalized unit, but negatively correlated with height and LF in ms2. High-density lipoprotein cholesterol (HDL-C) was negatively correlated with SBP, DBP, and MAP, reflecting its protective effect against elevated BP. In conclusion, the 8-week EGCG treatment decreased BP and increased the LF/HF ratio, reflecting increased sympathetic activity, either as a direct EGCG effect or an indirect compensatory response following BP reduction.
Practical Solutions and Value
Clinical trials play a crucial role in developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates ICD-11 standards, clinical protocols, and research into a single, easily accessible knowledge base for clinicians. In today’s healthcare environment, streamlining operations is crucial. Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally. By using AI, clinics can enhance their workflows and improve patient outcomes, reducing paper routine.
Learn more about how we can help at aidevmd.com.
